12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Adamas Pharmaceuticals, Forest Laboratories deal

Forest and Adamas partnered to develop and commercialize Adamas' Arimenda ( ADS-8704) in the U.S. to treat moderate to severe Alzheimer's disease. The product is a once-daily, fixed-dose combination of extended-release memantine and donepezil. Adamas will receive $65 million up front and...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >